Boston Biomedica, Inc.
This article was originally published in The Gray Sheet
Assets of wholly owned esoteric clinical reference lab subsidiary BBI Clinical Labs are purchased by Specialty Labs of Santa Monica, California for $9.5 mil. cash. The deal, announced Feb. 20, adds BBICL's expertise in Lyme disease and tick-borne pathogens and immunological/molecular analysis of HIV and viral hepatitis to Specialty's more than 3,500 clinical reference lab test offerings. Transaction includes transitional services agreement under which Bridgewater, Massachusetts-based BBI will support the integration of the divested unit over the remainder of 2001
You may also be interested in...
Experience and data from the study, which will use the same vector platform to deliver different transgenes for different diseases, could feed into the US FDA’s efforts to establish a public-private partnership to enable manufacturing of gene therapies for ultra-rare diseases.
Non-Hygiene Personal Care ‘Essential’ In California … For Now; COVID-19 Event Impacts; Cosmetics News In Brief
Santa Monica, CA-based law firm Conkle, Kremer and Engle warns that while all personal-care product businesses appear to be designated “essential” in the Golden State under its statewide “stay at home” order, officials could decide that the policy does not apply to manufacturers of non-hygiene products. More cosmetics news in brief.
Pink Sheet Podcast: US FDA’s Chloroquine EUA And Coronavirus Treatment Accelerator, Novartis Receives No Penalty For Zolgensma Problems
Pink Sheet reporters and editors discuss the effects of the chloroquine emergency use authorization, FDA efforts to speed coronavirus treatment development, and the agency decision against penalizing Novartis over Zolgensma’s data integrity problems.